Ablation therapy following unsuccessful electrical cardioversion in patients with persistent atrial fibrillation.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
07 10 2024
Historique:
received: 17 06 2024
accepted: 23 09 2024
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 7 10 2024
Statut: epublish

Résumé

Electrical cardioversion (ECV) a widely utilized intervention for persistent atrial fibrillation (AF) aimed at restoring sinus rhythm. However, ECV can be ineffective, raising questions about subsequent treatment options. This study aimed to compare the outcomes of non-ablation therapy versus ablation therapy following unsuccessful ECV. A total of 125 consecutive patients with persistent AF who underwent unsuccessful ECV between November 2017 and August 2023 was included in this retrospective analysis. Of these, 51.2% received only medical therapy (non-ablation therapy group, n = 64), while 48.8% underwent AF ablation (ablation therapy group, n = 61). Various ablation methods were employed, including catheter and thoracoscopic ablation. Ablation therapy was associated with significantly better AF-free survival compared to non-ablation therapy [hazard ratio (HR), 0.37; 95% confidence interval (CI) 0.22-0.61; p < 0.01]. There was no difference of AF-free survival between catheter ablation and thoracoscopic ablation groups (HR 0.79, 95% CI 0.34-1.83; p = 0.58). AF duration > 5 year (HR 1.51; 95% CI 0.930-2.437; p = 0.10), BMI ≤ 25 kg/m

Identifiants

pubmed: 39375426
doi: 10.1038/s41598-024-73989-2
pii: 10.1038/s41598-024-73989-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

23289

Informations de copyright

© 2024. The Author(s).

Références

Crijns, H. J. et al. Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study. Int. J. Cardiol.172, 588–594. https://doi.org/10.1016/j.ijcard.2014.01.099 (2014).
doi: 10.1016/j.ijcard.2014.01.099 pubmed: 24556445
Elhendy, A. et al. Predictors of unsuccessful electrical cardioversion in atrial fibrillation. Am. J. Cardiol.89, 83–86. https://doi.org/10.1016/s0002-9149(01)02172-5 (2002).
doi: 10.1016/s0002-9149(01)02172-5 pubmed: 11779532
Grönberg, T. et al. Can we predict the failure of electrical cardioversion of acute atrial fibrillation? The FinCV study. Pacing Clin. Electrophysiol.38, 368–375. https://doi.org/10.1111/pace.12561 (2015).
doi: 10.1111/pace.12561 pubmed: 25534241
Hellman, T. et al. Prediction of ineffective elective cardioversion of atrial fibrillation: a retrospective multi-center patient cohort study. BMC Cardiovasc. Disord. 17, 33. https://doi.org/10.1186/s12872-017-0470-0 (2017).
doi: 10.1186/s12872-017-0470-0 pubmed: 28100174 pmcid: 5241921
Mlodawska, E., Tomaszuk-Kazberuk, A., Lopatowska, P., Kaminski, M. & Musial, W. J. CHA2 DS2 VASc score predicts unsuccessful electrical cardioversion in patients with persistent atrial fibrillation. Intern. Med. J.47, 275–279. https://doi.org/10.1111/imj.13319 (2017).
doi: 10.1111/imj.13319 pubmed: 27860070
Ebert, M. et al. Predictors, management, and outcome of cardioversion failure early after atrial fibrillation ablation. Europace. 20, 1428–1434. https://doi.org/10.1093/europace/eux327 (2018).
doi: 10.1093/europace/eux327 pubmed: 29165582
Nakamaru, R. et al. Usefulness of failed electrical cardioversion for early recurrence after catheter ablation for atrial fibrillation as a predictor of future recurrence. Am. J. Cardiol.123, 794–800. https://doi.org/10.1016/j.amjcard.2018.11.039 (2019).
doi: 10.1016/j.amjcard.2018.11.039 pubmed: 30558757
Kamada, H. et al. Impact of pre-ablation direct current cardioversion for persistent atrial fibrillation to predict recurrence of atrial fibrillation after catheter ablation. Int. Heart J.63, 828–836. https://doi.org/10.1536/ihj.22-135 (2022).
doi: 10.1536/ihj.22-135 pubmed: 36184544
Hindricks, G. et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J.42, 373–498. https://doi.org/10.1093/eurheartj/ehaa612 (2021).
doi: 10.1093/eurheartj/ehaa612 pubmed: 32860505
Joglar, J. A. et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice guidelines. J. Am. Coll. Cardiol.83, 109–279. https://doi.org/10.1016/j.jacc.2023.08.017 (2024).
doi: 10.1016/j.jacc.2023.08.017 pubmed: 38043043
Salis, F., Locci, G., Mura, B. & Mandas, A. Anemia in elderly patients-the impact of hemoglobin cut-off levels on geriatric domains. Diagnostics (Basel). 13, 191. https://doi.org/10.3390/diagnostics13020191 (2023).
doi: 10.3390/diagnostics13020191 pubmed: 36673001
Richter, B., Gwechenberger, M., Socas, A., Marx, M. & Gössinger, H. D. Frequency of recurrence of atrial fibrillation within 48 hours after ablation and its impact on long-term outcome. Am. J. Cardiol.101, 843–847. https://doi.org/10.1016/j.amjcard.2007.11.021 (2008).
doi: 10.1016/j.amjcard.2007.11.021 pubmed: 18328850
Wynn, G. J. et al. Efficacy of catheter ablation for persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials. Circ. Arrhythm. Electrophysiol.7, 841–852. https://doi.org/10.1161/CIRCEP.114.001759 (2014).
doi: 10.1161/CIRCEP.114.001759 pubmed: 25132078
Nielsen, J. C. et al. Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial. Heart. 103, 368–376. https://doi.org/10.1136/heartjnl-2016-309781 (2017).
doi: 10.1136/heartjnl-2016-309781 pubmed: 27566295
Hsu, L. F. et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl. J. Med.351, 2373–2383. https://doi.org/10.1056/NEJMoa041018 (2004).
doi: 10.1056/NEJMoa041018 pubmed: 15575053
Marrouche, N. F. et al. Catheter ablation for atrial fibrillation with heart failure. N Engl. J. Med.378, 417–427. https://doi.org/10.1056/NEJMoa1707855 (2018).
doi: 10.1056/NEJMoa1707855 pubmed: 29385358
Sohns, C. et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl. J. Med.389, 1380–1389. https://doi.org/10.1056/NEJMoa2306037 (2023).
doi: 10.1056/NEJMoa2306037 pubmed: 37634135
Tønnesen, J. et al. Short- and long-term risk of atrial fibrillation recurrence after first time ablation according to body mass index: a nationwide Danish cohort study. Europace. 25, 425–432. https://doi.org/10.1093/europace/euac225 (2023).
doi: 10.1093/europace/euac225 pubmed: 36480430
Pallisgaard, J. L. et al. Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study. Eur. Heart J.39, 442–449. https://doi.org/10.1093/eurheartj/ehx466 (2018).
doi: 10.1093/eurheartj/ehx466 pubmed: 29020388
Li, Z. et al. Long atrial fibrillation duration and early recurrence are reliable predictors of late recurrence after radiofrequency catheter ablation. Front. Cardiovasc. Med.9, 864417l. https://doi.org/10.3389/fcvm.2022.864417 (2022).
doi: 10.3389/fcvm.2022.864417
Kirchhof, P. et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl. J. Med.383, 1305–1316. https://doi.org/10.1056/NEJMoa2019422 (2020).
doi: 10.1056/NEJMoa2019422 pubmed: 32865375
Go, A. S. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in Atrial Fibrillation (ATRIA) Study. JAMA. 285, 2370–2375. https://doi.org/10.1001/jama.285.18.2370 (2001).
doi: 10.1001/jama.285.18.2370 pubmed: 11343485
Dilaveris, P. E. & Kennedy, H. L. Silent atrial fibrillation: epidemiology, diagnosis, and clinical impact. Clin. Cardiol.40, 413–418. https://doi.org/10.1002/clc.22667 (2017).
doi: 10.1002/clc.22667 pubmed: 28273368 pmcid: 6490532
Mannhart, D. et al. Clinical validation of 5 direct-to-consumer wearable smart devices to detect atrial fibrillation: BASEL Wearable Study. JACC Clin. Electrophysiol.9, 232–242. https://doi.org/10.1016/j.jacep.2022.09.011 (2022).
doi: 10.1016/j.jacep.2022.09.011
Kim, D. et al. Age and outcomes of early rhythm control in patients with atrial fibrillation: nationwide cohort study. JACC Clin. Electrophysiol.8, 619–632. https://doi.org/10.1016/j.jacep.2022.02.014 (2022).
doi: 10.1016/j.jacep.2022.02.014 pubmed: 35589174
MacGregor, R. M. et al. Impact of age on atrial fibrillation recurrence following surgical ablation. J. Thorac. Cardiovasc. Surg.162, 1516–1528e1. https://doi.org/10.1016/j.jtcvs.2020.02.137 (2021).
doi: 10.1016/j.jtcvs.2020.02.137 pubmed: 32389465
Guckel, D. et al. The effect of diabetes mellitus on the recurrence of atrial fibrillation after ablation. J. Clin. Med.10, 4863. https://doi.org/10.3390/jcm10214863 (2021).
doi: 10.3390/jcm10214863 pubmed: 34768382 pmcid: 8584917
Haldar, S. et al. Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial. Eur. Heart J.41, 4471–4480. https://doi.org/10.1093/eurheartj/ehaa658 (2020).
doi: 10.1093/eurheartj/ehaa658 pubmed: 32860414 pmcid: 7767634
Schmidt, A. S. Maximum-fixed energy shocks for cardioverting atrial fibrillation. Eur. Heart J.41, 626–631. https://doi.org/10.1093/eurheartj/ehz585 (2020).
doi: 10.1093/eurheartj/ehz585 pubmed: 31504412

Auteurs

Hyo Jin Lee (HJ)

Division of Cardiology, Department of Internal Medicine, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.

Su Hyun Lee (SH)

Division of Cardiology, Department of Internal Medicine, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.

Juwon Kim (J)

Division of Cardiology, Department of Internal Medicine, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.

Ju Youn Kim (JY)

Division of Cardiology, Department of Internal Medicine, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.

Seung-Jung Park (SJ)

Division of Cardiology, Department of Internal Medicine, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.

Kyoung-Min Park (KM)

Division of Cardiology, Department of Internal Medicine, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.

Young Keun On (YK)

Division of Cardiology, Department of Internal Medicine, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. yk.on@samsung.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH